Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea

Published:2018-12-10 Issue:7 Volume:42 Page:851-857
ISSN:1720-8386
Container-title:Journal of Endocrinological Investigation
language:en
Short-container-title:J Endocrinol Invest

Author:

Khaloo P.,Asadi Komeleh S.,Alemi H.,Mansournia M. A.,Mohammadi A.,Yadegar A.,Afarideh M.,Esteghamati S.,Nakhjavani M.,Esteghamati A.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s40618-018-0991-0.pdf

Reference42 articles.

1. Ogurtsova K et al (2017) IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 128:40–50

2. 2 Diabetes. 2013 Sep. https://www.ncbi.nlm.nih.gov/books/NBK361996/ , C.R.P.i.B.I.O.O.C.A.f.D.a.T.i.H.-O.S.-a.T.-L.T.i.T

3. Ahren B (2010) Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 3:31–41

4. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548):1696–1705

5. Derosa G et al (2014) Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam Clin Pharmacol 28(2):221–229

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials;Nutrition, Metabolism and Cardiovascular Diseases;2021-12

2. Effects of sitagliptin on serum lipid levels in patients with type 2 diabetes;Journal of Cardiovascular Medicine;2021-11-08

3. Effective Reduction of Inflammatory and Coagulation Factors using Sitagliptin in Type 2 Diabetes;Iranian Red Crescent Medical Journal;2021-02-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3